News

The new facilities will double the current pharmaceutical development capacity. The new non-GMP formulation development facility will provide clients with greater flexibility and speed in formulation and process

The extended-release liquid methylphenidate is indicated for the treatment of ADHD in patients from six years of age by administering once a day. Pfizer emerging markets and established

According to the deal, PharmAthene will use the technology in the production of recombinant butyrylcholinesterase (rBChE) bioscavenger. rBChE absorbs toxins including organophosphorous compounds and certain pesticides with the

The NOA, which is issued based on patent application13/610,217, includes claims for using icosapent ethyl, or EPA, including Vascepa, in lowering triglycerides through the daily administration of about

The randomized trial did not meet its primary endpoint of progression-free survival (PFS). According to the analysis of patients enrolled, median PFS was 8.3 months in the experimental

Licence extension includes the use of Zytiga as a combination therapy along with prednisone or prednisolone to treat metastatic castration-resistant prostate cancer (mCRPC), in men who are asymptomatic

Featuring vanilla and strawberry flavours, Souvenaid product is a 125ml once-a-day drink, which includes a combination of nutrients that are naturally present in food. People living with Alzheimer’s

According to the deal, BPC will provide manufacturing services and license proprietary fractionation and purification manufacturing process for Respiratory Syncytial Virus (RSV) intravenous immune globulin to ADMA. BPC

The novel inhibitor of the enzyme glutathione S-transferase P1 1,Telintra activates Jun kinase, which regulates cellular growth and differentiation of blood precursor cells. Telintra investigational agent is being